Duchenne Muscular Dystrophy (DMD) Treatment Includes Physiotherapy, Medication, Surgery And Regular Monitoring Of Metabolic And Cardiac Function

Duchenne Muscular Dystrophy (DMD) Treatment
Duchenne Muscular Dystrophy (DMD) Treatment

Duchenne muscular dystrophy is a common genetic disease and it is characterized by progressive muscle weakness. The disease leads to premature death. It affects males more often than females. Duchenne is caused by a mutation in the dystrophin gene, which is located on the X chromosome. A mutation in the dystrophin gene is rare, and occurs in less than one in 5,000 babies.

There is no cure for Duchenne Muscular Dystrophy (DMD) Treatment currently, whereas it can be delayed with certain medications. The disease is caused by a gene mutation that results in loss of dystrophin protein production in the muscles. Dystrophin is important in maintaining the strength and flexibility of muscle cells. It helps to stabilize the plasma membrane of muscle fibers, which in turn keeps muscle cells from breaking down.

Symptoms of DMD may spread to other parts of the body and they can begin in the hips and thighs. These symptoms can progress to the arms and shoulders, and the disease may affect the heart. Duchenne Muscular Dystrophy (DMD) Treatment includes medication, physiotherapy, and regular monitoring of metabolic and cardiac function. If symptoms do not respond to medication, surgery may be considered. Surgery can help to relieve muscle tension and correct scoliosis.

The Duchenne Muscular Dystrophy (DMD) Treatment Market is expanding as a result of increasing investments in research and development to find an effective DMD treatment.

There are also newer treatments that can help people with DMD live longer and more active lives. These treatments include the use of stem cells to replace muscle cells. Some researchers are also researching ways to turn stem cells into muscle cells. These therapies are still in the early stages of development, as there are some promising ideas on the horizon.

Another Duchenne Muscular Dystrophy (DMD) Treatment is the use of a medication called eteplirsen. The medication promotes the production of dystrophin. It has been studied in preclinical trials and clinical trials. However, there have been some concerns about the efficacy of eteplirsen. The medication is available in tablet form.

Children suffering with DMD can also receive physical and occupational therapy. Occupational therapists help children develop a daily exercise plan to help them maintain muscle function. Physical therapists can also assist children with breathing problems and other health complications. Pfizer Inc., declared that they are initiating the Phase 3 study for evaluating fordadistrogene movaparvovec, the investigational mini-dystrophin gene therapy in three sites in the U.S., in April 2022.

Comments

Post a Comment

Popular posts from this blog

Sarcopenia Treatment; Training and Physical Exercise Is Key to Counteract Sarcopenia

Image
Sarcopenia Treatment A primary Sarcopenia Treatment is exercise. Researchers have identified resistance training as the specific form of exercise that is most beneficial to individuals with sarcopenia. At present, resistance exercise, protein supplementation, and vitamin D have been established as the basic treatment of sarcopenia. Recent clinical trials on sarcopenia therapies such as physical exercise, nutraceutical, and pharmaceutical interventions have revealed that exercise is the only effective strategy shown to alleviate sarcopenia. Sarcopenia refers to a loss of muscle mass specifically related to aging. It's normal to lose some muscle mass as people age. Sarcopenia has been defined as an age-related, involuntary loss of skeletal muscle mass and strength. Although aging is the main cause of sarcopenia, some other factors contribute to the loss of muscle mass. Getting little or no physical activity on a regular basis puts people at an increased risk of developing sarcopenia
Read more

Increasing Developments by Key Players Are Expected To Augment the Growth of the Global Digital Pathology Market

Image
 Digital Pathology Digital Pathology Market , by Product Type (Image Analysis Software, Scanner {Bright Field Scanner, Fluorescence Scanner}, Services {Installation & Integration, Maintenance Services, Consulting Services}), by Therapeutic Area (Oncology, Hematology, Autoimmune Disorder, Dermatology, and Others), by Technology (Immunohistochemistry, ISH & FISH, Immunofluorescence and others) End User (Pharmaceutical & Biotechnology Companies, Diagnostic Labs, Hospital Laboratories, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030. The global Digital Pathology Market is anticipated to reach an estimated value of US$ 884.4 million in 2023 and is projected to grow at a CAGR of 12.2% from 2023 to 2030. Market Overview: Digital pathology refers to the practice of digitizing glass slides containing tissue samples and analyzing them using digital imaging technology
Read more

Patient-Centered Medical Home; Is Used To Offer High-Standard, Inexpensive Primary Care

Image
Patient-Centered Medical Home The Patient-Centered Medical Home is a care model in which individuals are involved in a direct association with a chosen physician who organizes a supportive team of hospital experts, takes cooperative accountability for the comprehensive incorporated care offered to the patient, and sponsors and arranges suitable care with other professional physicians and community sources as per requirements. Use of PCMH develop disciplinary care teams to enhance care management and care administration of patient populaces focusing to increase safety, efficacy and standard in patient care. PCMH practices can enhance care and take benefits of private or public inducement payments that are offered to patients. The Patient Protection and Affordable Care Act (ACA) provides extra federal expenditure to regions for health homes helping Medicaid receivers. Supplier groups and hospitals can visit their federal and state officials and private insurers’ websites for data on exp
Read more